| Brianna Gardyne, MED, EDS, NCSP | |
|
320 Queen St, Boscawen, NH 03303-1128 | |
| (802) 356-4736 | |
| Not Available |
| Full Name | Brianna Gardyne |
|---|---|
| Gender | Female |
| Speciality | Psychologist - School |
| Location | 320 Queen St, Boscawen, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619741436 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TS0200X | Psychologist - School | SP-122 (New Hampshire) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Brianna Gardyne, MED, EDS, NCSP 320 Queen St, Boscawen, NH 03303-1128 Ph: (802) 356-4736 | Brianna Gardyne, MED, EDS, NCSP 320 Queen St, Boscawen, NH 03303-1128 Ph: (802) 356-4736 |
News Archive
A new analysis led by the University of Pittsburgh Graduate School of Public Health offers insights for nonprofit hospitals in implementing community health improvement programs. In a special issue of the Journal of Health Care for the Poor and Underserved that focuses on the Affordable Care Act, a multidisciplinary team of Pitt researchers explore published research on existing community benefit programs at U.S. hospitals and explain how rigorous implementation of such programs could help hospitals both meet federal requirements and improve the health of the populations they serve.
Cyclacel Pharmaceuticals, Inc. announced today 1-year survival data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes refractory to hypomethylating agents, such as azacitidine and decitabine. The data were reported at a poster presentation at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.
A pair of studies by The Children's Hospital of Philadelphia (CHOP) and State Farm® identify factors that may lead teens to drive with multiple peer passengers and, then, how those passengers may affect their driver's behavior just before a serious crash. The studies were published today in the Journal of Adolescent Health.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
A team of researchers from the Massachusetts General Hospital Center for Engineering in Medicine (MGH-CEM) has found the first evidence of cell-to-cell communication by amino acids, the building blocks of proteins, rather than by known protein signaling agents such as growth factors or cytokines.
› Verified 1 days ago